Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba-yama, Aoba-ku, Sendai, Japan.
School of Pharmacy, Iwate Medical University, Nishitokuta, Yahaba, Iwate, Japan.
Nat Chem. 2015 Sep;7(9):737-43. doi: 10.1038/nchem.2308. Epub 2015 Aug 3.
The structural complexity and diversity of natural products make them attractive sources for potential drug discovery, with their characteristics being derived from the multi-step combination of enzymatic and non-enzymatic conversions of intermediates in each biosynthetic pathway. Intermediates that exhibit multipotent behaviour have great potential for use as starting points in diversity-oriented synthesis. Inspired by the biosynthetic pathways that form complex metabolites from simple intermediates, we developed a semi-synthetic process that combines heterologous biosynthesis and artificial diversification. The heterologous biosynthesis of fungal polyketide intermediates led to the isolation of novel oligomers and provided evidence for ortho-quinonemethide equivalency in their isochromene form. The intrinsic reactivity of the isochromene polyketide enabled us to access various new chemical entities by modifying and remodelling the polyketide core and through coupling with indole molecules. We thus succeeded in generating exceptionally diverse pseudo-natural polyketides through this process and demonstrated an advanced method of using biosynthetic intermediates.
天然产物的结构复杂性和多样性使它们成为潜在药物发现的有吸引力的来源,其特点源自每个生物合成途径中中间体的多步酶促和非酶促转化的组合。表现出多效行为的中间体具有作为多样性导向合成起点的巨大潜力。受从简单中间体形成复杂代谢物的生物合成途径的启发,我们开发了一种半合成工艺,将异源生物合成和人工多样化结合起来。真菌聚酮中间体的异源生物合成导致了新型寡聚物的分离,并为它们在异咯嗪形式中的邻醌亚甲醚等价物提供了证据。异咯嗪聚酮的内在反应性使我们能够通过修饰和重塑聚酮核心以及与吲哚分子偶联来获得各种新的化学实体。因此,我们通过该过程成功地生成了异常多样的伪天然聚酮,并展示了一种使用生物合成中间体的先进方法。